Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT ID: NCT04558502
Last Updated: 2022-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
339 participants
INTERVENTIONAL
2022-01-05
2022-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rescue Therapy for Helicobacter Pylori Eradication Treatment
NCT04531059
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
NCT05419674
High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment
NCT03557437
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04678492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
minocycline-based bismuth quadruple regimen for 14 days
Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
Minocycline hydrochloride capsule
Antibiotic for H. pylori eradication
Amoxicillin
Antibiotic for H. pylori eradication
colloidal bismuth pectin
Gastric mucosal protective drug with anti-H. pylori effect
esomeprazole
Proton pump inhibitor
clarithromycin-based bismuth quadruple regimen for 14 days
Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
Clarithromycin
Antibiotic for H. pylori eradication
Amoxicillin
Antibiotic for H. pylori eradication
colloidal bismuth pectin
Gastric mucosal protective drug with anti-H. pylori effect
esomeprazole
Proton pump inhibitor
minocycline-based bismuth quadruple regimen for 10 days
Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 10 days.
Minocycline hydrochloride capsule
Antibiotic for H. pylori eradication
Amoxicillin
Antibiotic for H. pylori eradication
colloidal bismuth pectin
Gastric mucosal protective drug with anti-H. pylori effect
esomeprazole
Proton pump inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minocycline hydrochloride capsule
Antibiotic for H. pylori eradication
Clarithromycin
Antibiotic for H. pylori eradication
Amoxicillin
Antibiotic for H. pylori eradication
colloidal bismuth pectin
Gastric mucosal protective drug with anti-H. pylori effect
esomeprazole
Proton pump inhibitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* H. pylori (+) determined by either the 14C-or 13C-urea breath test or the gastric mucosal tissue rapid urease test and pathological section staining
* Treatment-naive patients for eradication of H.pylori infection
* Fully informed and agreed to participate in this study
Exclusion Criteria
* Allergy to any of the study drugs
* Use of any drug that could influence the study results 4 weeks before the study,such as antibiotics,bismuth agent,PPI or H2 receptor antagonist (H2RA)
* Previous gastric or esophageal surgery
* Patients with malignancy or severe comorbidity
* Pregnancy,lactation or alcohol abuse
* Patients with poor treatment compliance or could not express themselves correctly
* Participation in other clinical studies recently (within 3 months of enrollment in this clinical study)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qin Du, master
Role: PRINCIPAL_INVESTIGATOR
2nd Affiliated Hospital,School of Medicine,Zhejiang University,China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-584
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.